Patients with chronic kidney disease (CKD) who receive a gadolinium-based contrast agent (GBCA) have a low risk of developing nephrogenic systemic fibrosis (NSF), a systematic review and meta-analysis ...
Nephrogenic systemic fibrosis (NSF) was first described in 2000 as a scleromyxedema-like illness that presented with cutaneous fibrosis in 14 patients receiving chronic hemodialysis (Cowper et al, ...